Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients
- 作者：Kazuo Ogawa ; Tetsuko Kojima ; Chinami Matsumoto ; Satoshi Kamegai ; Takuya Oyama ; Yukari Shibagaki ; Hiroshi Muramoto ; Tetsuo Kawasaki ; Hiroshi Fujinaga ; Kozo Takahashi ; Hiroaki Hikiami ; Hirozo Goto ; Chiz
- 关键词：Kampo medicine ; Keishibukuryogan ; Responder ; SELDI– ; TOF MS ; Cross detector ; Peak separability analysis ; Haptoglobin
- 刊名：Clinical Biochemistry
- 出版年：2007
- 期刊代码：55_00099120
- 类别：med
- 出版时间：October 2007
- 卷：40
- 期：15
- 页码：1113-1121
- 文件大小：1227 K
摘要
Kampo (Japanese traditional herbal) medicines are now ethically used in Japan as pharmaceutical grade prescription drugs. However, there are distinct groups of responders and non-responders to Kampo medicines. We searched for biomarker candidates to discriminate responders from non-responders to keishibukuryogan (KBG); one of the most frequently used Kampo medicines.
rong>Design and methods: rong>
A combination of SELDI technology and a decision tree analysis with proprietary developed bioinformatics tools was applied to 41 (32 for tree construction and 9 for validation test) plasma samples obtained from rheumatoid arthritis (RA) patients. A candidate biomarker protein was identified using LC–MS/MS.
rong>Results: rong>
The constructed tree with measurable reliability contained only a single peak which was identified as haptoglobin alpha 1 chain (Hpα1).
rong>Conclusion: rong>
Hpα1 is a biomarker candidate for discriminating responders from non-responders to KBG treatment for RA. The present results may open the way to the establishment of “evidence-based” complementary and alternative medicine.